Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
COSTS AND EXPENSES:    
Research and development $ 28,211,460 $ 19,219,603
General and administrative 10,749,183 9,594,170
Total costs and expenses 38,960,643 28,813,773
LOSS FROM OPERATIONS (38,960,643) (28,813,773)
OTHER INCOME (EXPENSE):    
Warrant issuance expense (470,000)  
Gain on valuation of warrants 1,000,000  
Interest income, net 387,147 152,519
Total other income, net 917,147 152,519
LOSS BEFORE INCOME TAXES (38,043,496) (28,661,254)
INCOME TAX BENEFIT (60,000) (60,000)
NET LOSS $ (37,983,496) $ (28,601,254)
BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (3.11) $ (4.05)
DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (3.11) $ (4.05)
SHARES USED IN COMPUTING BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 12,221,571 7,055,665
SHARES USED IN COMPUTING DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 12,221,571 7,055,665